Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3

Yukiko Yamamoto-Watanabe, Mitsunori Watanabe, Mandy Jackson, Hiroyuki Akimoto, Kazuhiro Sugimoto, Minoru Yasujima, Yasuhito Wakasaya, Etsuro Matsubara, Takeshi Kawarabayashi, Yasuo Harigaya, Alastair R. Lyndon, Mikio Shoji

Research output: Contribution to journalArticlepeer-review


Cystatin C (CC) is a cysteine protease inhibitor abundantly expressed in the central nervous system. Bunina bodies, small eosinophilic intraneuronal inclusions, are stain positive for CC and are the most specific histological hallmark of amyotrophic lateral sclerosis (ALS). In this study, employing a latex turbidimetric immunoassay, levels of CC in cerebrospinal fluid (CSF) were quantified in 130 age-matched individuals with either a neurological disorder [ALS, Alzheimer's disease (AD), Parkinson's disease (PD), tauopathy (TP), multiple system atrophy (MSA), chronic inflammatory demyelinating polyneuropathy (CIDP)] or no known neurological condition (normal control, NC). The CC level in CSF was found to be correlated with the age during the investigation but not the protein concentration. There was no difference in CC levels between NC and ALS or CIDP cases, whereas CC levels were significantly lower in MSA compared with NC. Of the 130 cases, 96 were genotyped, and G/A or A/A polymorphism at +73 within the CST3 gene was found in 28 individuals. The CC level was significantly lower in the combined group of G/A and A/A genotypes compared with GIG. The present data demonstrate that the level of CC in CSF should not be considered as a biomarker of ALS, but there is a correlation between CC levels and the CST3 genotype. (C) 2010 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)140-145
Number of pages6
JournalBrain Research
Publication statusPublished - 18 Nov 2010

Cite this